ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Kaken Obtains Aadi’s Fyarro, Comm
Pink SheetReal-world evidence from expanded access programs and a natural history external control played important roles in recent US FDA decisions on the suitability of the accelerated approval pathway for C
Pink SheetThe European Medicines Agency is due to decide this week whether to recommend pan-EU marketing authorization for several products, including two treatments that are yet to be approved anywhere in the
Pink SheetThe European Medicines Agency on 14 November said that Eisai/Biogen’s early Alzheimer’s disease drug, Leqembi (lecanemab), should be approved for marketing across the EU, having previously rejected th